Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Prenatal Methamphetamine Exposure and Adverse Neonatal Outcomes: A Nationwide Cohort Study

R. Gabrhelík, S. Skurtveit, B. Nechanská, M. Handal, M. Mahic, V. Mravčík

. 2021 ; 27 (2) : 97-106. [pub] 20200723

Language English Country Switzerland

Document type Journal Article

Grant support
NV16-28157A MZ0 CEP Register

BACKGROUND: There is limited knowledge on the adverse outcomes in newborns after maternal methamphetamine (MA) use during pregnancy. OBJECTIVES: To compare neonatal outcomes in newborns exposed to MA with the newborns of opioid-exposed mothers and of mothers from the general population (GP). METHOD: A cohort study using nationwide registries in Czechia (2000-2014). Women hospitalized with a main diagnosis of MA use disorder during pregnancy (n = 258) and their newborns were defined as MA-exposed. The comparison groups consisted of women (n = 199) diagnosed with opioid use disorder during pregnancy, defined as opioid-exposed, and women (n = 1,511,310) with no substance use disorder diagnosis (GP). The neonatal outcomes studied were growth parameters, gestational age, preterm birth, and Apgar score. To explore the associations between MA exposure and neonatal outcomes, regression coefficients (b) and odds ratios from multivariable linear and binary logistic regression were estimated. RESULTS: MA-exposed women had similar socio-economic characteristics to opioid-exposed, both of which were worse than in the GP. After adjustment, MA exposure was associated with a more favourable birthweight when compared to the opioid-exposed (adjusted mean differences [aMD] b = 122.3 g, 95% CI: 26.0-218.5) and length (aMD b = 0.6 cm, 0.0-1.1). Unadjusted results from the comparison with the GP showed that the MA group had poorer neonatal outcomes, especially in the growth parameters. Adjustment for background characteristics had a profound effect on the comparison with the GP. After adjustment, MA exposure was associated only with a slightly reduced birthweight (aMD b = -63.0 g, -123.0 to -3.1) and birth length (aMD b = -0.3 cm, -0.6 to 0.0). CONCLUSIONS: Although the observed negative outcomes were large in the MA-exposed newborns, the adjustment had a profound effect on the comparison with the GP, indicating the large influence of lifestyle and socio-economic factors in these high-risk pregnancies. MA-exposed newborns had better neonatal outcomes compared to opioids-exposed.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026243
003      
CZ-PrNML
005      
20211026133100.0
007      
ta
008      
211013s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000509048 $2 doi
035    __
$a (PubMed)32702698
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Gabrhelík, Roman $u Department of Addictology, First Faculty of Medicine, Charles University, Prague, Czechia, roman.gabrhelik@lf1.cuni.cz $u Department of Addictology, General University Hospital in Prague, Prague, Czechia, roman.gabrhelik@lf1.cuni.cz
245    10
$a Prenatal Methamphetamine Exposure and Adverse Neonatal Outcomes: A Nationwide Cohort Study / $c R. Gabrhelík, S. Skurtveit, B. Nechanská, M. Handal, M. Mahic, V. Mravčík
520    9_
$a BACKGROUND: There is limited knowledge on the adverse outcomes in newborns after maternal methamphetamine (MA) use during pregnancy. OBJECTIVES: To compare neonatal outcomes in newborns exposed to MA with the newborns of opioid-exposed mothers and of mothers from the general population (GP). METHOD: A cohort study using nationwide registries in Czechia (2000-2014). Women hospitalized with a main diagnosis of MA use disorder during pregnancy (n = 258) and their newborns were defined as MA-exposed. The comparison groups consisted of women (n = 199) diagnosed with opioid use disorder during pregnancy, defined as opioid-exposed, and women (n = 1,511,310) with no substance use disorder diagnosis (GP). The neonatal outcomes studied were growth parameters, gestational age, preterm birth, and Apgar score. To explore the associations between MA exposure and neonatal outcomes, regression coefficients (b) and odds ratios from multivariable linear and binary logistic regression were estimated. RESULTS: MA-exposed women had similar socio-economic characteristics to opioid-exposed, both of which were worse than in the GP. After adjustment, MA exposure was associated with a more favourable birthweight when compared to the opioid-exposed (adjusted mean differences [aMD] b = 122.3 g, 95% CI: 26.0-218.5) and length (aMD b = 0.6 cm, 0.0-1.1). Unadjusted results from the comparison with the GP showed that the MA group had poorer neonatal outcomes, especially in the growth parameters. Adjustment for background characteristics had a profound effect on the comparison with the GP. After adjustment, MA exposure was associated only with a slightly reduced birthweight (aMD b = -63.0 g, -123.0 to -3.1) and birth length (aMD b = -0.3 cm, -0.6 to 0.0). CONCLUSIONS: Although the observed negative outcomes were large in the MA-exposed newborns, the adjustment had a profound effect on the comparison with the GP, indicating the large influence of lifestyle and socio-economic factors in these high-risk pregnancies. MA-exposed newborns had better neonatal outcomes compared to opioids-exposed.
650    _2
$a kohortové studie $7 D015331
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a novorozenec $7 D007231
650    _2
$a methamfetamin $x škodlivé účinky $7 D008694
650    _2
$a těhotenství $7 D011247
650    12
$a komplikace těhotenství $7 D011248
650    12
$a výsledek těhotenství $7 D011256
650    _2
$a předčasný porod $7 D047928
650    12
$a zpožděný efekt prenatální expozice $7 D011297
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Skurtveit, Svetlana $u Norwegian Institute of Public Health, Oslo, Norway $u Norwegian Centre for Addiction Research at the University of Oslo, Oslo, Norway
700    1_
$a Nechanská, Blanka $u Department of Addictology, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Handal, Marte $u Norwegian Institute of Public Health, Oslo, Norway
700    1_
$a Mahic, Milada $u Norwegian Institute of Public Health, Oslo, Norway
700    1_
$a Mravčík, Viktor $u Department of Addictology, First Faculty of Medicine, Charles University, Prague, Czechia $u National Monitoring Centre for Drugs and Addiction, Office of the Government of the Czech Republic, Prague, Czechia
773    0_
$w MED00007942 $t European addiction research $x 1421-9891 $g Roč. 27, č. 2 (2021), s. 97-106
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32702698 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133107 $b ABA008
999    __
$a ok $b bmc $g 1715070 $s 1146750
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 27 $c 2 $d 97-106 $e 20200723 $i 1421-9891 $m European addiction research $n Eur Addict Res $x MED00007942
GRA    __
$a NV16-28157A $p MZ0
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...